Products for Research Use Only
RegisterLogin

Imatinib (Mesylate)

CAT: 0804-HY-50946-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-50946-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
CAS Number
220127-57-1
Product Name Alternative
STI571 (Mesylate) ; CGP-57148B (Mesylate)
UNSPSC
12352005
Hazard Statement
H361
Target
Autophagy; Bcr-Abl; c-Kit; PDGFR
Type
Reference compound
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Imatinib-Mesylate.html
Purity
99.98
Solubility
DMSO : 125 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL
Smiles
O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
Molecular Formula
C30H35N7O4S
Molecular Weight
589.71
Precautions
H361
References & Citations
[1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97 (8) :2440-8|[4]Maj E, et al. Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model. Int J Mol Sci. 2015 Nov 13;16 (11) :27191-207.|[5]Tanaka S, et al. Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. Ann Thorac Surg. 2016 Jul 23. pii: S0003-4975 (16) 30523-9|[6]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Adv Sci (Weinh) . 2024 Jul 2:e2402107.|Anticancer Drugs. 2014 Jul;25 (6) :673-82.|Biomed Chromatogr. 2019 Dec;33 (12) :e4674.|BMC Med. 2022 Aug 24;20 (1) :257|Bone Res. 2024 Apr 10;12 (1) :24.|Clin Cancer Res. 2025 May 1;31 (9) :1686-1699.|Harvard Medical School LINCS LIBRARY|J Bioenerg Biomembr. 2012 Feb;44 (1) :155-61.|J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Apr 1:1255:124526.|J Pers Med. 2023 Jan 11;13 (1) :146.|Mol Cell Biochem. 2020 Jan;463 (1-2) :67-78|Nat Commun. 2025 Feb 14;16 (1) :1631.|Nat Commun. 2025 Jul 24;16 (1) :6777.|Nat Immunol. 2023 Sep;24 (9) :1443-1457.|Oncotarget. 2018 Apr 24;9 (31) :22158-22183. |Patent. US20220242943A1.|Pharmaceutics. 2023 Sep 12;15 (9) :2305.|Phytomedicine. 2024 Nov:134:155937.|PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |PLoS One. 2017 Jun 1;12 (6) :e0178619.|Research Square Preprint. 2023 Nov 20.|University of Heidelberg. 2025.|ACS Appl Mater Interfaces. 2025 Jan 15;17 (2) :2884-2898.|Acta Pharmacol Sin. 2023 May;44 (5) :984-998.|Arch Pharm (Weinheim) . 2022 Oct 10; e2200367.|Bioanalysis. 2018 Jul;10 (14) :1099-1113.|Biochem Biophys Res Commun. 2025 May 15:771:152027.|Biochem Pharmacol. 2023 Mar:209:115442.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2024 Jan:170:115778.|Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomolecules. 2022 Jun 11;12 (6) :819.|bioRxiv. 2024 Dec 20:2024.12.19.629301.|bioRxiv. 2024 June 09.|bioRxiv. 2025 February 26.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Jun 13:2025.06.13.659082.|bioRxiv. 2025 Sep 30.|Blood Vessel Thromb Hemost. 2025 Nov 17.|Breast Cancer Res Treat. 2025 Jun;211 (2) :467-478.|Cancer Biol Ther. 2019;20 (6) :877-885.|Cancer Commun (Lond) . 2025 Nov 10.|Cancer Lett. 2019 Apr 10:447:105-114.|Cancer Med. 2019 Sep;8 (11) :5352-5366.|Cancer Res. 2025 Jan 2;85 (1) :101-117.|Cell Biosci. 2020 Feb 12;10:16.|Cell Biosci. 2024 Jun 29;14 (1) :87.|Cell Chem Biol. 2018 Aug 16;25 (8) :996-1005.e4.|Cell Death Dis. 2022 Apr 20;13 (4) :384.|Cell Metab. 2022 Mar 1;34 (3) :424-440.e7.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Clin Cancer Res. 2020 Aug 15;26 (16) :4349-4359.|Clin Chem. 2019 Dec;65 (12) :1522-1531. |Clin Sci. 2021 Jul 30;135 (14) :1751-1765.|Clin Transl Med. 2025 Feb;15 (2) :e70231.|Commun Biol. 2024 Jul 10;7 (1) :843.|Curr Res Toxicol. 2024 Jul 14:7:100187.|Drug Des Devel Ther. 2022 Aug 4;16:2545-2557.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|EMBO J. 2025 Nov 3.|EMBO Mol Med. 2021 Apr 9;13 (4) :e13144.|Eur J Pharmacol. 2021 Apr 15:897:173944.|Eur J Pharmacol. 2021 Dec 15:913:174633.|Eur J Pharmacol. 2021 Sep 5:906:174217.|Exp Hematol Oncol. 2024 Dec 18;13 (1) :121.|Gastric Cancer. 2023 Sep;26 (5) :677-690.|Heliyon. 2024 Aug 22;10 (16) :e36640.|Hum Cell. 2025 Jan 3;38 (2) :38.|In Vivo. 2024 Sep-Oct;38 (5) :2310-2317.|Inflamm Regen. 2022 Sep 26;42 (1) :44.|Int J Mol Sci. 2023 Feb 2;24 (3) :2849.|J Biomed Inform. 2023 Jun:142:104383.|J Cell Biochem. 2023 Sep;124 (9) :1404-1422.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100.|J Med Chem. 2016 Sep 22;59 (18) :8456-72. |J Med Chem. 2019 Jul 11;62 (13) :6083-6101.|J Med Chem. 2019 May 23;62 (10) :5006-5024. |J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Tradit Complement Med. 2023 Nov 22;14 (3) :321-334.|J Transl Med. 2024 Dec 20;22 (1) :1119.|Med Sci Monit. 2017 Aug 6:23:3808-3816.|Microchem J. 2025 Apr.|Microvasc Res. 2025 May 7:104816.|Mol Carcinog. 2024 Apr 17|Mol Carcinog. 2024 Jan;63 (1) :75-93.|Mol Ther. 2023 Feb 1;31 (2) :503-516.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Oncogene. 2022 Mar;41 (12) :1821-1834.|Oncogene. 2024 May 17.|Oncotarget. 2016 Jul 19;7 (29) :45562-45574.|Oncotarget. 2017 Nov 15;8 (67) :111110-111118. |Patent. US20200276189A1.|Patent. US20220064117A1.|Patent. US20220288064A1.|Patent. US20230158019A1.|Patent. US20230226111A1.|Patent. US20240238271A1.|Patent. US20240325538A1.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Res Sq. 2025 Apr 14.|Research Square Preprint. 2021 May.|Sci Immunol. 2023 Mar 17;8 (81) :eade4656.|Sci Rep. 2025 Feb 8;15 (1) :4779.|Sci Rep. 2025 May 30;15 (1) :18978.|Sci Signal. 2019 Jul 16;12 (590) . pii: eaav7259.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sensor Actuat B-Chem. 2021, 128991.|Signal Transduct Target Ther. 2023 Mar 1;8 (1) :90.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Ther Adv Med Oncol. 2019 May 17:11:1758835919849757.|Theranostics. 2021 Jan 1;11 (6) :2691-2705.|Toxicol Lett. 2022 Jul 15:365:11-23.|Toxicol Lett. 2022 Jun 15:363:11-26.|Viruses. 2021 May 31;13 (6) :1035.

Chemical Information

Imatinib Mesylate

Imatinib methanesulfonate is a methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an anticoronaviral agent, an antineoplastic agent, a tyrosine kinase inhibitor and an apoptosis inducer. It contains an imatinib.

CAS Number220127-57-1
PubChem CID123596
IUPAC Namemethanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Molecular FormulaC30H35N7O4S
Molecular Weight589.7
Topological Polar Surface Area149
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Heavy Atom Count42
Formal Charge0
Complexity799
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O
InChI
InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
InChIKey
YLMAHDNUQAMNNX-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Imatinib Mesylate
CAS: 220127-57-1
CID: 123596
Formula: C30H35N7O4S
MW: 589.7
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight589.7
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass589.24712380
Monoisotopic Mass589.24712380
Topological Polar Surface Area149 Ų
Heavy Atom Count42
Formal Charge0
Complexity799
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-132386S-01Imatinib-d8 (mesylate)
HY-15463-01Imatinib
HY-15463S1-01Imatinib-d4
HY-111849-01Imatinib carbaldehyde
HY-15463S-01Imatinib-d8
HY-135638-01Imatinib Acid
HY-15463R-01Imatinib (Standard)
HY-G0017-01N-Desmethyl imatinib
HY-131275-01Imatinib Impurity E
HY-Z4127-01Imatinib impurity 2

Alternative Products

CatalogName
RM-I132080-01Imatinib Mesylate
ALX-270-492-M025Imatinib . mesylate

Popular Products